Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079264 | 0.90 | NR3C1 (0.40) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL7074009 | 0.90 | NR3C1 (0.48) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL5961472 | 0.86 | CCR2 (0.63) | SPRNR3C1CCR2CCR5 | |
| SCHEMBL5961525 | 0.86 | CCR2 (0.54) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL5961522 | 0.85 | CCR2 (0.53) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL7137484 | 0.84 | SPR (0.43) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL7079006 | 0.84 | MEN1 (0.45) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL5961535 | 0.84 | CCR2 (0.42) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL7078063 | 0.84 | SPR (0.40) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL5961427 | 0.84 | CCR2 (0.51) | SPRNR3C1CCR2CCR5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | SPR 430/4885NR3C1 673/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.